Chemotherapy was not associated with cognitive decline in older adults with breast and colorectal cancer: Findings from a prospective cohort study

Medical Care

Volumn 50, Issue 10, 2012, Pages 849-855

  Shaffer, Victoria A ^a,b   Merkle, Edgar C ^b   Fagerlin, Angela ^c,d   Griggs, Jennifer J ^c   Langa, Kenneth M ^c,d   Iwashyna, Theodore J ^c,d  

^a School of Health Professions   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

breast cancer; cancer care; cancer survivors; chemotherapy; cognition; colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

AGED; AGING; ARTICLE; ATTENTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; COGNITION; COGNITIVE DEFECT; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; FOLLOW UP; FUNCTIONAL STATUS; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MEDICARE; MEMORY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; TELECONSULTATION;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC PROTOCOLS; BAYES THEOREM; BREAST NEOPLASMS; COGNITION DISORDERS; COLORECTAL NEOPLASMS; FEMALE; HEALTH BEHAVIOR; HUMANS; INTERVIEWS AS TOPIC; MALE; MEMORY; PROSPECTIVE STUDIES;

EID: 84866547159     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31825a8bb0     Document Type: Article

References (58)

1. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute. Available at: http://seer.cancer.gov/csr/1975-2008/.
2. Stat bite: cancer survivors in the United States. J Natl Cancer Inst. 2008;100:236.
3. Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Translation. Washington, DC: National Academies Press; 2006.
4. Gross J. Chemotherapy fog is no longer ignored as an illusion. New York Times. April 29, 2007. Available at: http://nytimes.com/2007/04/29/health/ 29chemo.html. Accessed November 17, 2010.
5. Brody JE. The fog that follows chemotherapy. New York Times. August 3, 2009. Available at: http://www.nytimes.com/2009/08/04/health/04brod.html?-r = 1. Accessed December 13, 2010.
6. Boykoff N, Moieni M, Subramanian SK. Confronting chemobrain: an in-depth look at survivors' reports of work, social networks, and health care response. J Cancer Surviv. 2009;3:223-232.
7. Mehnert A, Scherwath A, Schirmer L, et al. The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns. 2007;66:108-118.
8. Soussain C, Ricard D, Fike JR, et al. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374:1639-1651.
9. Correa DD, Ahles TA. Neurocognitive changes in cancer survivors. Cancer J. 2008;14:396-400.
10. Ahles TA, Saykin A. Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Invest. 2001;19:812-820.
11. Ahles TA, Saykin AJ, Furstenburg CT, et al. Neuropsychological impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485-493.
12. Wefel JS, Lenzi R, Theriault RL, et al. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer. 2004;100:2292-2299.
13. Quesnel C, Savard J, Ivers H. Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat. 2009;116:113-123.
14. Weis J, Poppelreuter M, Bartsch HH. Cognitive deficits as long-term side effects of adjuvant therapy in breast cancer patients: "subjective" complaints and "objective" neuropsychological test results. Psychoon-cology. 2009;18:775-782.
15. Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348-3356.
16. Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434-4440.
17. Janelsins MC, Kohli S, Mohile SG, et al. An update on cancer-and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38:431-438.
18. Phillips KM, Jim HS, Small BJ, et al. Cognitive functioning after cancer treatment: a 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer. 2012;118:1925-1932.
19. Donovan KA, Small BJ, Andrykowski MA, et al. Cognitive functioning after adjuvant chemotherapy and/or radiation for early-stage breast cancer. Cancer. 2005;104:2499-2507.
20. Jenkins V, Shilling V, Deutsch G, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828-834.
21. Jim HSL, Donovan KA, Small BJ, et al. Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer. 2009;115:1776-1783.
22. Mehlsen M, Pedersen AD, Jensen AB, et al. No indications of cognitive side-effects in a prospective study of breast cancer patients receiving adjuvant chemotherapy. Psychooncology. 2009;18:248-257.
23. Debess J, Riis JØ, Engebjerg MC, et al. Cognitive function after adjuvant treatment for early breast cancer: a population-based longitudinal study. Breast Cancer Res Treat. 2010;121:91-100.
24. Tager FA, McKinley PS, Schnabel FR, et al. The cognitive effects of chemotherapy in post-menopausal breast cancer patients: a controlled longitudinal study. Breast Cancer Res Treat. 2010;123:25-34.
25. Plassman B, Langa K, Fisher G, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148:427-434.
26. Helfin LH, Meyerowitz BE, Hall P, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97:854-856.
27. Khan NF, Mant D, Carpenter L, et al. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: a database study. Br J Cancer. 2011;105:S29-S37.
28. Baxter NN, Durham SB, Phillips KA, et al. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy. J Am Geriatr Soc. 2009;57:403-411.
29. Heck JE, Albert SM, Franco R, et al. Patterns of dementia diagnosis in surveillance, epidemiology, and end results breast cancer survivors who use chemotherapy. J Am Geriatr Soc. 2008;56:1687-1692.
30. Graham JE, Rockwood K, Beattie BL, et al. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet. 1997;349:1793-1796.
31. Dewey ME, Saz P. Dementia, cognitive impairment and mortality in persons aged 65 and over living in the community: a systematic review of the literature. Int J Geriatr Psychiatry. 2001;16:751-761.
32. Health and Retirement Study. Available at: http://hrsonline.isr.umich. edu/. Accessed December 8, 2011.
33. Nattinger AB, Laud PW, Bajorunaite R, et al. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv Res. 2004;39(pt 1):1733-1749.
34. Gold HT, Do HT. Evaluation of three algorithms to identify incident breast cancer in Medicare claims data. Health Serv Res. 2007;42:2056-2069.
35. Yabroff KR, Warren JL, Banthin J, et al. Comparison of approaches for estimating prevalence costs of care for cancer patients: what is the impact of data source? Med Care. 2009;47(suppl 1):S64-S69.
36. McBean AM, Warren JL, Babish JD. Measuring the incidence of cancer in elderly Americans using Medicare claims data. Cancer. 1994;73:2417-2425.
37. Lamont EB, Herndon JE III, Weeks JC, et al. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. J Natl Cancer Inst. 2005;97:1080-1083.
38. Herzog AR, Wallace RB. Measures of cognitive functioning in the AHEAD Study. J Gerontol B Psychol Sci Soc Sci. 1997;52(special no.):37-48.
39. Welsh KA, Breitner JCS, Magruder-Habib KM. Detection of dementia in the elderly using telephone screening of cognitive status. Neuro-psychiatry Neuropsychol Behav Neurol. 1993;6:103-110.
40. Iwashyna TJ, Ely EW, Smith DM, et al. Long term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304:1787-1794.
41. Khatri M, Nickolas T, Moon YP, et al. CKD associates with cognitive decline. J Am Soc Nephrol. 2009;20:2427-2432.
42. Ofstedal MB, Fisher GG, Herzog AR. Documentation of Cognitive Functioning Measures in the Health and Retirement Study; 2005. Available at: http://hrsonline.isr.umich.edu/sitedocs/userg/dr-006.pdf. Accessed November 17, 2010.
43. Bates D, Maechler M. (2010). lme4: linear mixed-effects models usingS4 classes. R package version 0.999375-34. Available at: http://CRAN.R-project.org/ package = lme4. Accessed June 1, 2012.
44. Plummer M 2010. rjags: Bayesian graphical models using MCMC. R package version 2.1.0-5. Available at: http://CRAN.R-project.org/pack age= rjags. Accessed June 1, 2010.
45. Griggs JJ, Sorbero MES, Lyman GH. Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med. 2005;165:1267-1273.
46. Griggs JJ, Culakova E, Sorbero MES, et al. Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol. 2007;25:277-284.
47. Browne MW, Cudeck R. Alternative ways of assessing model fit. In: Bollen KA, Long JS, eds. Testing Structural Equation Models. Newbury Park, CA: Sage; 2005:136-162.
48. Anderson-Hanley C, Sherman ML, Riggs R, et al. Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature. J Int Neuropsychol Soc. 2003;9:967-982.
49. Faletti MG, Sanfilippo A, Maruff P, et al. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60-70.
50. Jansen CE, Miaskowski C, Dodd M, et al. A metaanalysis of studies of the effects of cancer and chemotherapy on various domains of cognitive function. Cancer. 2004;104:2222-2233.
51. Stewart A, Bielajew C, Collins B, et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol. 2006;20:76-89.
52. Crooks VC, Petitti DB, Robins SB, et al. Cognitive domains associated with performance on the Telephone Interview for Cognitive Status-modified. Am J Alzheimers Dis Other Demen. 2006;21:45-53.
53. Jansen SJ, Otten W, Stiggelbout AM. Review of determinants of patients' preferences for adjuvant therapy in cancer. J Clin Oncol. 2004;22:3181-3190.
54. Fried TR, Bradley EH, Towle VR, et al. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061-1066.
55. Rosenbaum PR, Ross RN, Silber JH. Minimum distance matched sampling with fine balance in an observational study of treatment for ovarian cancer. J Am Stat Assoc. 2007;102:75-83.
56. Langa KM, Chernew ME, Kabeto MU, et al. National estimates of the quantity and cost of informal caregiving for the elderly with dementia. J Gen Intern Med. 2001;16:770-778.
57. Langa KM, Larson EB, Karlawish JH, et al. Trends in the prevalence and mortality of cognitive impairment in the United States: is there evidence of a compression of cognitive morbidity? Alzheimers Dement. 2008;4:134-144.
58. Alzheimer's Association. Early onset dementia: a national challenge, a future crisis; 2006. Available at: http://www.alz.org/national/docu ments/report-earlyonset-full.pdf. Accessed December 1, 2011.